Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02487979
Title Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | child
Covered Countries USA | CAN


No variant requirements are available.